2. IDH1 gene mutation in patients with glioblastoma
Main Article Content
Abstract
The IDH1 gene mutation is considered a molecular biomarker, playing a crucial role in the prognosis of patients with glioblastoma. A cross-sectional retrospective study was conducted on 129 patients with glioblastoma who underwent surgery at Viet Duc University Hospital and Hanoi Medical University Hospital from 2017 to 2021. The results showed that IDH1 gene mutation occurred in 15 out of 129 patients (11.6%) all of which were heterozygous mutations, specifically the G395A (R132H) point mutation. IDH1 mutation status and age group (< 65 years and ≥ 65 years) were found to be correlated with the overall survival time of patients with glioblastoma (p < 0.05).
Article Details
Keywords
IDH1 mutation, Glioblastoma
References
2. Aum DJ, Kim DH, Beaumont TL, et al. Molecular and cellular heterogeneity: the hallmark of glioblastoma. Neurosurg Focus. 2014;37(6):E11. doi:10.3171/2014.9.FOCUS14 521
3. Parsons DW, Jones S, Zhang X, et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme. Science. 2008;321(5897):1807-1812. doi:10.1126/scien ce.1164382
4. Loenarz C, Schofield CJ. Expanding chemical biology of 2-oxoglutarate oxygenases. Nat Chem Biol. 2008;4(3):152-156. doi:10.1038/nchembio0308-152
5. Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012;483(7390):479-483. doi:10.1038/nature1 0866
6. Beiko J, Suki D, Hess KR, et al. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro-Oncol. 2014;16(1):81-91. doi:10.1093/neuonc/not159
7. Anh N Tran, Albert Lai, Sichen Li, et al. Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry. Neuro Oncol. 2014;16(3):414-420. doi:10.1093/neuonc/not1 98
8. Teske N, Karschnia P, Weller J, et al. Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma? J Neurooncol. 2022;156(2):317-327. doi:10.1007/s11060-021-03912-6
9. Molenaar RJ, Verbaan D, Lamba S, et al. The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. Neuro-Oncol. 2014;16(9):1263-1273. doi:10.1093/neuonc/nou005
10. Mai Thế Cảnh, Nguyễn Duy Huề. Nghiên cứu đặc điểm hình ảnh và giá trị chẩn đoán của cộng hưởng từ đối với u nguyên bào thần kinh đệm hai bán cầu. Tạp chí Điện quang Việt Nam. 2012;5:31-37.
11. Marc Sanson, Yannick Marie, Sophie Paris, et al. Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas. Journal of Clinical Oncology. 2009;27(25):4150-4154. https://doi.org/10.1200/JCO.2009.21.9832
12. Liang J, Lv X, Lu C, et al. Prognostic factors of patients with Gliomas – an analysis on 335 patients with Glioblastoma and other forms of Gliomas. BMC Cancer. 2020;20(1):35. doi:10.1186/s12885-019-6511-6
13. Bleeker FE, Molenaar RJ, Leenstra S. Recent advances in the molecular understanding of glioblastoma. J Neurooncol. 2012;108(1):11-27. doi:10.1007/s11060-011-07 93-0
14. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807-1812. doi:10.1126/scien ce.1164382
15. Nobusawa S, Watanabe T, Kleihues P, et al. IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas. Clin Cancer Res. 2009;15(19):6002-6007. doi:10.1158/1078-0432.CCR-09-0715
16. Sonoda Y, Kumabe T, Nakamura T, et al. Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci. 2009;100(10):1996-1998. doi:10.1111/j.1349-70 06.2009.01270.x
17. Bleeker FE, Atai NA, Lamba S, et al. The prognostic IDH1R132mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol (Berl). 2010;119(4):487-494. doi:10.1007/s004 01-010-0645-6